Home / Market News / $SIBN
benzinga Corporate Catalyst Impact 75/100 ● positive

SI-BONE Receives FDA Clearance For Its iFuse Granite Onyx System

Sep 28, 2026, 8:09 PM UTC · Primary ticker $SIBN

SI-BONE announced FDA 510(k) clearance for its iFuse Granite Onyx System, a new product designed to address loosening in spinal fusion constructs, particularly for patients with compromised bone. This expands the company's market opportunity beyond the pelvis and could improve patient outcomes and reduce revision rates in spinal fusion procedures.

SI-BONE (SIBN) received FDA 510(k) clearance for its iFuse Granite Onyx System, a significant development for the medical device company. This new product addresses a critical clinical challenge of loosening in spinal fusion constructs, especially for patients with compromised bone, which previously led to high revision rates. This clearance expands SI-BONE's market opportunity beyond its traditional pelvic applications, opening up a new segment within spinal fusion. In the short term, this could lead to increased investor confidence and a positive stock reaction for SIBN. Long-term, successful adoption of Onyx could drive revenue growth and solidify SI-BONE's position in the spinal fusion market, offering a key opportunity for traders looking at growth in the medical device sector.

$SIBN positive New product clearance expands market opportunity
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.